ICER backs cost-ef­fec­tive­ness of Vas­cepa, Xarel­to; Epizyme's lead drug wins speedy US re­view

→ Drug cost-ef­fec­tive­ness watch­dog ICER on Wednes­day un­veiled pre­lim­i­nary find­ings from its draft re­port on ad­di­tive car­dio­vas­cu­lar dis­ease ther­a­pies: Amarin’s $AM­RN fish oil pill Vas­cepa and J&J’s $JNJ blood thin­ner Xarel­to. Find­ings sug­gest the ther­a­pies of­fer sur­vival ben­e­fit over op­ti­mal med­ical man­age­ment, the in­sti­tute said. “As­sum­ing clin­i­cal sig­nals…hold for pa­tients treat­ed with these in­ter­ven­tions and cur­rent net prices, the base-case re­sults sug­gest that costs for treat­ment with ei­ther ri­varox­a­ban (Xarel­to) or icos­apent eth­yl (Vas­cepa) would fall be­low com­mon­ly cit­ed thresh­olds for cost-ef­fec­tive­ness.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.